COVID-19 outbreak highlights gaps in Indian pharma’s quality management
categories: Americas, Asia Pacific, Australia, EMEAI, RATTE Aurelie, Investing (Investment Management), COVID-19, Asset Managers (Quant or Fundamental), Asset Owners, Hedge Funds, ESG Products & Services, Equities
The coronavirus outbreak has applied supply chain shocks to companies relying on China for their raw materials and key supplies. The outbreak has thrown questions of quality management and resilience into sharp relief for Indian pharma companies that could have significant repercussions on the supply of medicines globally. India is the largest provider of generic drugs globally, and generic drugs account for 20% of global exports in terms of volumes. This report explores the quality-management issues facing the pharmaceutical industry highlighted by disruptions in the global supply of medicine caused by the COVID-19 pandemic.